Evidence map›Paper›PMID 24317510›Full record

ArticleOncogene2014

An integrative analysis reveals functional targets of GATA6 transcriptional regulation in gastric cancer.

R Sulahian, F Casey, J Shen, Z R Qian, H Shin, S Ogino, B A Weir, F Vazquez, X S Liu, W C Hahn and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Early Gastric Cancer: identification of molecular markers able to distinguish submucosa-penetrating lesions with different prognosis.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

R Sulahian1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [2] Department of Medicine, Harvard Medical School, Boston, MA, USA.
F CaseyNovartis Institutes for Biomedical Research, Emeryville, CA, USA.
J ShenNovartis Institutes for Biomedical Research, Emeryville, CA, USA.
Z R Qian1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [2] Department of Pathology, Harvard Medical School and Brigham & Women's Hospital, Boston, MA, USA.
H ShinDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
S Ogino1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [2] Department of Pathology, Harvard Medical School and Brigham & Women's Hospital, Boston, MA, USA.
B A WeirDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
F VazquezDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
X S LiuDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
W C Hahn1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [2] Department of Medicine, Harvard Medical School, Boston, MA, USA [3] Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA.
A J Bass1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [2] Department of Medicine, Harvard Medical School, Boston, MA, USA [3] Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA.
V ChanNovartis Institutes for Biomedical Research, Emeryville, CA, USA.
R A Shivdasani1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [2] Department of Medicine, Harvard Medical School, Boston, MA, USA [3] Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA.
Dana-Farber Cancer Institute · USNovartis (United States) · USHarvard University · US

Funding

Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI EL-BARDEESY, NABEEL, SELLERS, WILLIAM R · 2007 to 2023
$33.2M
The Dana-Farber Cancer Institute Cancer Target Discovery and Development CenterU01CA176058 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2013 to 2021
$7.8M
Computational Models for Mechanisms of Global Transcription RegulationR01HG004069 · NHGRI · DANA-FARBER CANCER INST · PI LIU, XIAOLE SHIRLEY · 2006 to 2013
$3.6M
Epigenetic Events and Colorectal Cancer EpidemiologyR01CA151993 · NCI · DANA-FARBER CANCER INST · PI OGINO, SHUJI · 2010 to 2014
$2.6M
Genome Discovery and Validation in Upper Gastrointestinal CarcinomasK08CA134931 · NCI · DANA-FARBER CANCER INST · PI BASS, ADAM JOEL · 2008 to 2012
$774k
NCI NIH HHS K08 CA134931NCI NIH HHS K08CA134931NCI NIH HHS P50 CA127003NCI NIH HHS P50CA127003NCI NIH HHS R01 CA151993NCI NIH HHS R01CA151993NCI NIH HHS U01 CA176058NHGRI NIH HHS R01 HG004069NHGRI NIH HHS R01HG4069
6 · The paper itself

Abstract

Lineage-restricted transcription factors (TFs) are frequently mutated or overexpressed in cancer and contribute toward malignant behaviors; however, the molecular bases of their oncogenic properties are largely unknown. As TF activities are difficult to inhibit directly with small molecules, the genes and pathways they regulate might represent more tractable targets for drug therapy. We studied GATA6, a TF gene that is frequently amplified or overexpressed in gastric, esophageal and pancreatic adenocarcinomas. GATA6-overexpressing gastric cancer cell lines cluster in gene expression space, separate from non-overexpressing lines. This expression clustering signifies a shared pathogenic group of genes that GATA6 may regulate through direct cis-element binding. We used chromatin immunoprecipitation and sequencing (ChIP-seq) to identify GATA6-bound genes and considered TF occupancy in relation to genes that respond to GATA6 depletion in cell lines and track with GATA6 mRNA (synexpression groups) in primary gastric cancers. Among other cellular functions, GATA6-occupied genes control apoptosis and govern the M-phase of the cell cycle. Depletion of GATA6 reduced the levels of the latter transcripts and arrested cells in G2 and M phases of the cell cycle. Synexpression in human tumor samples identified likely direct transcriptional targets substantially better than consideration only of transcripts that respond to GATA6 loss in cultured cells. Candidate target genes responded to the loss of GATA6 or its homolog GATA4 and even more to the depletion of both proteins. Many GATA6-dependent genes lacked nearby binding sites but several strongly dependent, synexpressed and GATA6-bound genes encode TFs such as MYC, HES1, RARB and CDX2. Thus, many downstream effects occur indirectly through other TFs and GATA6 activity in gastric cancer is partially redundant with GATA4. This integrative analysis of locus occupancy, gene dependency and synexpression provides a functional signature of GATA6-overexpressing gastric cancers, revealing both limits and new therapeutic directions for a challenging and frequently fatal disease.

Indexed as

Gene Expression Regulation, NeoplasticApoptosisBinding SitesCell CycleCell LineageCell Line, TumorCell ProliferationEpigenesis, GeneticGATA4 Transcription FactorGATA6 Transcription FactorGene Expression ProfilingHistonesHumansRNA, MessengerSignal TransductionStomach NeoplasmsGATA4 protein, humanGATA4 Transcription FactorGATA6 protein, humanGATA6 Transcription FactorHistonesRNA, MessengerTranscription Factors

Identifiers

PMID24317510
PMCPMC4050037
OpenAlexW2043095119

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.